Significant response to atezolizumab plus bevacizumab treatment in unresectable hepatocellular carcinoma with major portal vein tumor thrombus: a case report
2021 · BMC Gastroenterology · 9 citations
https://doi.org/10.1186/s12876-021-02053-4
K
Kaori Kuramitsu
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
117
Papers
1.3K
Citations
16
h-index
33
i10-index
Kaori Kuramitsu is an academic researcher from Organ Technologies (Japan). The author has contributed to research in topics: Hepatocellular Carcinoma Treatment and Prognosis & Pancreatic and Hepatic Oncology Research & Cholangiocarcinoma and Gallbladder Cancer Studies. The author has an h-index of 16, co-authored 100 publications.
ORCID: 0000-0002-9843-6800Papers by this author
worksSupplementary Material for: A novel method using gadolinium-ethoxybenzyl diethylenetriamine pentaacetate acid-enhanced magnetic resonance imaging for predicting post-hepatectomy liver failure in hepatocellular carcinoma patients with a major portal vein tumor thrombus
2024 · Figshare · 0 citations
https://doi.org/10.6084/m9.figshare.24981225
Supplementary Material for: Prognostic impact of inflammation-based scores for extrahepatic cholangiocarcinoma
2022 · Figshare · 0 citations
https://doi.org/10.6084/m9.figshare.18782606
Supplementary Material for: A novel method using gadolinium-ethoxybenzyl diethylenetriamine pentaacetate acid-enhanced magnetic resonance imaging for predicting post-hepatectomy liver failure in hepatocellular carcinoma patients with a major portal vein tumor thrombus
2024 · Figshare · 0 citations
https://doi.org/10.6084/m9.figshare.24989994
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat